1. **Factors associated with virological response to etravirine in non nucleoside reverse transcriptase inhibitor experienced HIV-1 infected patients.**

2. **High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.**

3. **Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients.**

4. **Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.**

5. **Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.**

6. **Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.**

7. **The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection.**

8. **Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.**

9. **A new human immunodeficiency virus derived from gorillas.**


20 Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.
21. **Cerebral microbleeds are frequent in infective endocarditis: a case-control study.**

22. **Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.**
AIDS. 2009 Nov 13;23(17):2289-300.

23. **Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy.**

24. **Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.**
J Infect Dis. 2009 Sep 15;200(6):973-83

25. **Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts < 350 cells/microl.**

26. **Systematic evaluation and description of anal pathology in HIV-infected patients during the HAART era.**
Abramowitz L, Benabderrahmane D, Baron G, Walker F, Yeni P, Duval X.

27. **Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France.**

28. **Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.**

Clin Infect Dis. 2009 Apr 15;48(8):1138-51


30 Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).


31 How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalité 2000 survey and death certificates.


32 Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4.


33 Interruption of antiretroviral therapy is associated with increased plasma cystatin C.


AIDS. 2009 Jan 2;23(1):71-82.

34 Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial.


35 Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: nelfinavir.


36 Clinical and resistance consequences of misquantification of plasma and cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) RNA in samples from an HIV-1 subtype G-infected patient.


37 Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trial.


38 Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study.


Antivir Ther. 2009;14(1):75-83

39 Clinical pharmacokinetic of maraviroc]

Peytavin G.

Med Mal Infect. 2008 Mar;38 Suppl 1:S12-6

40 High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.


J Antimicrob Chemother. 2009 Feb;63(2):380-8

41 Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).


42 Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome.


Retrovirology. 2009 Sep 19;6:85.
43 No relation between in-utero exposure to HAART and intrauterine growth retardation.


AIDS. 2009 Jun 19;23(10):1235-43.

44 Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.


Clin Infect Dis. 2009 Apr 15;48(8):1138-51

45 Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4.


46 Amniocentesis and mother-to-child human immunodeficiency virus transmission in the Agence Nationale de Recherches sur le SIDA et les Hépatites Virales French Perinatal Cohort.


47 Tenofovir-Emtricitabine-Efavirenz in HIV-1-Infected Adults in Senegal: A 96-Week Pilot Trial in Treatment-Naive Patients.

Landman R, Poupard M, Diallo M, Gueye NF, Diakhate N, Ndiaye B, Kane CT, Trylesinski A, Diop H, Mboup S, Fall MB, Deleporte E, Benalycherif AD, Girard PM, Sow PS.

J Int Assoc Physicians AIDS Care (Chic Ill). 2009 Sep 15

48 Simplification and first validation of a short battery of patient questionnaires for clinical management of HIV-infected patients: The HIV-SQUAD (Symptom Quality of life Adherence) Questionnaire.


49 Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.


Roquebert B, Damond F, Brun-Vézinet F, Descamps D.


50 HIV genetic diversity and its consequences.